Education
About Us
Working with TipRanks
Follow Us
Immunic (IMUX)
NASDAQ:IMUX
IMUX Stock Chart & Stats
$0.57
-$0.01(-1.34%)
At close: 4:00 PM EST
$0.57
-$0.01(-1.34%)
Day’s Range― - ―
52-Week Range$0.55 - $1.39
Previous CloseN/A
Volume261.21K
Average Volume (3M)1.27M
Market Cap
$68.92M
Enterprise Value$136.60M
Total Cash (Recent Filing)$35.13M
Total Debt (Recent Filing)$126.00K
Price to Earnings (P/E)―
Beta1.20
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding120,284,720
10 Day Avg. Volume1,520,208
30 Day Avg. Volume1,266,234
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.44
Price to Sales (P/S)0.00
P/FCF Ratio-1.18
Enterprise Value/Market Cap1.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.90K
Enterprise Value/Ebitda-1.31
Forecast
1Y Price Target
$4.25Price Target Upside645.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.64
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe Phase 2 CALLIPER trial in progressive MS patients showcased statistically significant 24-Week confirmed disability improvement, with signals supportive of slowing disability progression across subgroups.
MS Market PositioningThere is significant interest in oral treatments for multiple sclerosis, with 40% of prescriptions being oral, which supports vidofludimus calcium's market positioning.
Treatment InnovationVidofludimus calcium offers a novel dual mechanism for disease modification in multiple sclerosis, providing both neuroprotection and relapse prevention.
Bears Say
Financing ChallengesThe financing overhang is still material, but there is a clear path to funding the company with the PIPE/2025 public offering funding structure through the ENSURE-1 and -2 trials.
Reduced Price TargetThe price target has been reduced from $10 to $8, based on basic and diluted share count adjustment.
Immunic News
IMUX FAQ
What was Immunic’s price range in the past 12 months?
Immunic lowest stock price was $0.55 and its highest was $1.39 in the past 12 months.
What is Immunic’s market cap?
Immunic’s market cap is $68.92M.
When is Immunic’s upcoming earnings report date?
Immunic’s upcoming earnings report date is May 07, 2026 which is in 137 days.
How were Immunic’s earnings last quarter?
Immunic released its earnings results on Nov 13, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.143 by $0.013.
Is Immunic overvalued?
According to Wall Street analysts Immunic’s price is currently Undervalued.
Does Immunic pay dividends?
Immunic does not currently pay dividends.
What is Immunic’s EPS estimate?
Immunic’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immunic have?
Immunic has 120,284,720 shares outstanding.
What happened to Immunic’s price movement after its last earnings report?
Immunic reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.143. Following the earnings report the stock price went down -6.579%.
Which hedge fund is a major shareholder of Immunic?
Currently, no hedge funds are holding shares in IMUX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunic Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.25 (645.61% Upside)
$4.25 (645.61% Upside)
Blogger Sentiment
Bullish
IMUX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.90%
12-Months-Change
Fundamentals
Return on Equity
-398.50%
Trailing 12-Months
Asset Growth
-37.15%
Trailing 12-Months
Company Description
Immunic
Immunic, Inc. (IMUX) is a clinical-stage biopharmaceutical company focused on developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company's lead product candidate, IMU-838, is an orally available, selective immune modulator that targets diseases such as multiple sclerosis and inflammatory bowel disease. Immunic leverages its proprietary technology platforms to advance its pipeline of innovative therapies.
IMUX Stock 12 Month Forecast
Average Price Target
$4.25
▲(645.61% Upside)
Technical Analysis
aTyr Pharma
―
vTv Therapeutics
―
NRX Pharmaceuticals
―
Equillium
―
Werewolf Therapeutics
―
Ownership Overview
1.05% Insiders
3.93% Mutual Funds
15.65% Other Institutional Investors
76.20% Public Companies and Individual Investors